BR0306861A - Combinações que compreendem epotilonas e antimetabólitos - Google Patents

Combinações que compreendem epotilonas e antimetabólitos

Info

Publication number
BR0306861A
BR0306861A BR0306861-7A BR0306861A BR0306861A BR 0306861 A BR0306861 A BR 0306861A BR 0306861 A BR0306861 A BR 0306861A BR 0306861 A BR0306861 A BR 0306861A
Authority
BR
Brazil
Prior art keywords
combination
simultaneous
hydrogen
optionally
lower alkyl
Prior art date
Application number
BR0306861-7A
Other languages
English (en)
Inventor
John Arthur Hohneker
M Mcsheehy J Paul
John David Rothermel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0306861A publication Critical patent/BR0306861A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMBINAçõES QUE COMPREENDEM EPOTILONAS E ANTIMETABóLITOS". é divulgada uma combinação que compreende (a) um antimetabólito antineoplásico e (b) um derivado de epotilona de fórmula I em que A representa O ou NR~ N~, em que R~ n~ é hidrogênio ou alquila inferior, R é hidrogênio ou alquila inferior, R<39> é metila, metóxi, etóxi, amino, metilamino, dimetilamino, aminometila ou metiltio e Z é O ou uma ligação, e opcionalmente, pelo menos um veículo farmaceuticamente aceitável e/ou, opcionalmente, um antidiarréico padrão; para uso simultâneo, separado ou seq³encial, em particular para o tratamento de uma doença proliferativa; uma composição farmacêutica que compreende uma tal combinação; o uso de uma tal combinação para a preparação de um medicamento para o tratamento de uma doença proliferativa, uma embalagem comercial ou produto que compreende uma tal combinação como uma preparação combinada para uso simultâneo, separado ou seq³encial; e a um processo de tratamento de um animal de sangue quente.
BR0306861-7A 2002-01-14 2003-01-13 Combinações que compreendem epotilonas e antimetabólitos BR0306861A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34862202P 2002-01-14 2002-01-14
US41617302P 2002-10-04 2002-10-04
PCT/EP2003/000232 WO2003057217A1 (en) 2002-01-14 2003-01-13 Combinations comprising epothilones and anti-metabolites

Publications (1)

Publication Number Publication Date
BR0306861A true BR0306861A (pt) 2004-11-03

Family

ID=26995808

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0306861-7A BR0306861A (pt) 2002-01-14 2003-01-13 Combinações que compreendem epotilonas e antimetabólitos

Country Status (16)

Country Link
US (3) US20060089327A1 (pt)
EP (2) EP2030618A3 (pt)
JP (1) JP2005513167A (pt)
KR (1) KR20040078123A (pt)
CN (1) CN1615136A (pt)
AU (1) AU2003235761A1 (pt)
BR (1) BR0306861A (pt)
CA (1) CA2471509A1 (pt)
IL (1) IL162595A0 (pt)
MX (1) MXPA04006822A (pt)
NO (1) NO20043279L (pt)
NZ (1) NZ533940A (pt)
PL (1) PL369670A1 (pt)
RU (1) RU2346686C2 (pt)
TW (1) TWI341728B (pt)
WO (1) WO2003057217A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4579351B2 (ja) 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
CZ305799B6 (cs) 2001-03-14 2016-03-23 Bristol-Myers Squibb Company Kombinace analogů epothilonu a chemoterapeutických činidel pro léčení proliferačních nemocí
KR20050051688A (ko) * 2002-10-09 2005-06-01 코산 바이오사이언시즈, 인코포레이티드 에포틸론(Еｐｏ) Ｄ ＋ 5-플루오로우라실(ＦＵ)/겜시타빈
MXPA06002393A (es) * 2003-09-02 2006-06-20 Novartis Ag Tratamiento de cancer con epotilomas.
US20050171167A1 (en) 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
MX2008012716A (es) * 2006-04-05 2008-10-14 Novartis Ag Combinaciones de agentes terapeuticos para el tratamiento de cancer.
EP2004163B1 (en) * 2006-04-05 2014-09-17 Novartis Pharma AG Combination of everolimus and vinorelbine
EP2571525A4 (en) 2010-05-18 2016-04-27 Cerulean Pharma Inc Compositions and methods for treating autoimmune and other diseases

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802005A (en) 1957-08-06 S-eluorourace
US2705727A (en) 1952-07-10 1955-04-05 Du Pont Synthesis of ureas
US2933498A (en) 1954-12-28 1960-04-19 Burroughs Wellcome Co 7-aminothiazolo-(5,4-d) pyrimidine
US3116282A (en) 1960-04-27 1963-12-31 Upjohn Co Pyrimidine nucleosides and process
US4393064A (en) 1976-03-05 1983-07-12 Sri International Process and composition for treatment of leukemia and process for preparing the same
US4357324A (en) 1981-02-24 1982-11-02 The United States Of America As Represented By The Department Of Health And Human Services Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine
US4760135A (en) 1984-09-06 1988-07-26 University Of Kentucky Research Foundation Phloretin and phlorizin derivative containing compounds
IL77133A (en) * 1984-12-04 1991-01-31 Lilly Co Eli Antineoplastic pharmaceutical compositions containing pentofuranoside derivatives,some new such compounds and their preparation
DE3773716D1 (de) 1986-03-24 1991-11-21 Nippon Kayaku Kk Verfahren zur herstellung von monosodiumsalz und dessen monohydrat von 1-beta-d-arabinofuranosylcytosin-5'stearylphosphat und diese enthaltende pharmazeutische zusammensetzung.
NL194430C (nl) 1989-01-05 2002-04-04 Otsuka Pharma Co Ltd Niet-injecteerbaar farmaceutisch preparaat met anti-kankerwerking.
ES2124257T4 (es) 1991-05-27 2012-03-23 Taiho Pharmaceutical Co., Ltd. Composición, método y equipo para la estimulación de la actividad antitumoral y para el tratamiento de tumores.
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
AU716610B2 (en) 1996-08-30 2000-03-02 Novartis Ag Method for producing epothilones, and intermediate products obtained during the production process
PT941227E (pt) 1996-11-18 2004-08-31 Biotechnolog Forschung Mbh Gbf Epothilona d sua preparacao e sua utilizacao como agente citostatico ou como agente de proteccao fitossanitaria
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
MY125921A (en) 1998-02-05 2006-08-30 Novartis Ag Compositions containing organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
MXPA00008365A (es) 1998-02-25 2002-11-07 Sloan Kettering Inst Cancer Sintesis de epotilonas, intermediarios y analogos de las mismas.
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
NZ511722A (en) 1998-11-20 2004-05-28 Kosan Biosciences Inc Recombinant methods and materials for producing epothilone and epothilone derivatives
JP2002533346A (ja) * 1998-12-22 2002-10-08 ノバルティス アクチエンゲゼルシャフト エポシロン誘導体およびそれらの抗腫瘍剤としての使用
US6262094B1 (en) * 1999-02-22 2001-07-17 Bristol-Myers Squibb Company C-21 modified epothilones
JP2002541200A (ja) * 1999-04-14 2002-12-03 デイナ−ファーバー キャンサー インスティチュート，インコーポレイテッド 癌の処置のための方法および組成物
GB9918429D0 (en) * 1999-08-04 1999-10-06 Novartis Ag Organic compounds
US20020045609A1 (en) * 2000-05-26 2002-04-18 Gary Ashley Epothilone derivatives and methods for making and using the same
CZ305799B6 (cs) * 2001-03-14 2016-03-23 Bristol-Myers Squibb Company Kombinace analogů epothilonu a chemoterapeutických činidel pro léčení proliferačních nemocí
TWI287986B (en) * 2001-12-13 2007-10-11 Novartis Ag Use of Epothilones for the treatment of the carcinoid syndrome

Also Published As

Publication number Publication date
CN1615136A (zh) 2005-05-11
TWI341728B (en) 2011-05-11
NZ533940A (en) 2007-06-29
EP2030618A3 (en) 2009-03-11
US20110082101A1 (en) 2011-04-07
AU2003235761A1 (en) 2003-07-24
WO2003057217A1 (en) 2003-07-17
EP2030618A2 (en) 2009-03-04
JP2005513167A (ja) 2005-05-12
KR20040078123A (ko) 2004-09-08
US20090298791A1 (en) 2009-12-03
EP1469847A1 (en) 2004-10-27
PL369670A1 (en) 2005-05-02
MXPA04006822A (es) 2004-12-08
TW200306185A (en) 2003-11-16
CA2471509A1 (en) 2003-07-17
RU2004124943A (ru) 2005-08-10
NO20043279L (no) 2004-08-05
IL162595A0 (en) 2005-11-20
US20060089327A1 (en) 2006-04-27
RU2346686C2 (ru) 2009-02-20

Similar Documents

Publication Publication Date Title
BRPI0413232B8 (pt) composto tendo atividade inibitória contra transportador dependente de sódio, composição farmacêutica compreendendo o composto, uso do composto na preparação de um medicamento e processo para a preparação do composto
EA201000643A1 (ru) Замещенное производное этилендиамина для лечения микобактериальных заболеваний и фармацевтическая композиция на его основе
DK2314582T3 (da) Heterocykliske forbindelser som antivirusmidler
BRPI0409227B8 (pt) &#34;composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)&#34;
BR0315959A (pt) Composto, composição farmacêutica uso do composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso e processo para a preparação do composto
BR0313160A (pt) Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
WO2007046868A3 (en) Thiazolidine derivatives and their uses as therapeutic agents
BRPI0413452A (pt) composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
AU2003242544A1 (en) New indolylpiperidine derivatives as potent antihistaminic and antiallergic agents
PA8591701A1 (es) Derivados de pirrolopirimidina
AR025959A1 (es) DERIVADOS DE TER.-BUTIL-(7-METIL-IMIDAZO[1,2,a]PIRIDIN-3-IL)-AMINA, PROCEDIMIENTO PARA SU PREPARACION, MEDICAMENTOS QUE LOS CONTIENEN, SU USO PARA LAPREPARACION DE UN MEDICAMENTO PARA LA INHIBICION DE NO-SINTASA Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
BRPI0108395B8 (pt) derivados de pirrolopirimidinona, processos de preparação e uso
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
BR0315777A (pt) Uso de derivados de piperazina como antagonistas ccr1
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
BR0315580A (pt) Derivados de metileno uréia
BRPI0513287A (pt) derivados de pirido-pirimidina, sua preparação, sua aplicação em terapêutica
CL2004001050A1 (es) Compuesto derivado de 3&#39;-[4-oxo-3-{[(ciclopropil o 2,2,2-trifluoroetil)amino]carbonil}-1,8-naftiridin-1(4h)-il]-3-sustituido-1-1&#39;-bifenil-4-il; composicion farmaceutica; y uso en el tratamiento o prevencion de asma, bronquitis cronica, enfermedad pul
BRPI0414948A (pt) derivados de pirazolo-e-imidazo pirimidina
BR9807950A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, o risco de doença inflamatória o risco da dor e para a preparação de um composto
BRPI0417858A (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
UY28377A1 (es) Agentes terapeuticos
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
BR0314195A (pt) Derivados de piridina substituìda como agentes antitumorais
TW200504029A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.